Back to homepage

Infectious disease

Neurological features of COVID-19 and their treatment: a review

Authors: Daniele Orsucci MD, Elena Caldarazzo Ienco MD, Gianpaolo Nocita MD, Alessandro Napolitano MD, Marco Vista MD

This review aims to summarize early findings on
the neurological features of COVID-19 and their treatment
approaches.

More

A brief note on randomized controlled trials and compassionate/off-label use of drugs in the early phases of the COVID-19 pandemic

Authors: Matteo Bassetti MD, PhD, Paolo Pelosi MD, FERS, Chiara Robba MD, PhD, Antonio Vena MD, PhD, Daniele Roberto Giacobbe MD

Randomized controlled trials (RCTs) are the best way to find effective and acceptable safe treatments for COVID-19 and any possible future outbreak. However, caution is needed when comparing the number of participants in RCTs with that of patients with COVID-19 treated with compassionate and/or off-label drugs to support the hypothesis that the latter are preferred by clinicians as an alternative to the former.

More

The journey of remdesivir: from Ebola to COVID-19

Authors: Joe Pardo PharmD, Ashutosh M Shukla MD, Gajapathiraju Chamarthi MD, Asmita Gupte MD

In this narrative review, an overview of Ebola and coronavirus outbreaks is provided as well as a summary of preclinical and clinical studies of remdesivir for Ebola and COVID-19.

More

Pharmacological treatment of COVID-19: lights and shadows

Authors: Francesco Menzella MD, Mirella Biava Msc, Chiara Barbieri MD, Francesco Livrieri MD, Nicola Facciolongo MD

The aim of this review is to explore COVID-19 treatment options and describe the potential benefits or disadvantages of their use in severe cases.

More

Psoriasis, biologic therapy, and the pandemic of the 21st century

Authors: Miguel Nogueira MD, Ron Vender MD, Tiago Torres MD, PhD

This editorial discusses the impact of COVID-19 on patients with psoriasis receiving biologic agents.

More